Partnership targets heart failure, the leading cause of death and a condition with limited treatment options
News | Heart Failure
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

March 15, 2024 — BioCardia, Inc. , a biotechnology company focused on advancing late-stage cell therapy interventions ...

Home March 15, 2024
Home
Partnership targets heart failure, the leading cause of death and a condition with limited treatment options
News | Cardiovascular Business
Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

March 15, 2024 —Renowned cardiovascular surgeon Gilbert H. L. Tang, MD, has been named Editor-in-Chief of JACC: Case ...

Home March 15, 2024
Home
Biotronik Launches Its Complete Conduction System Pacing (CSP) Solution Consisting of the World’s First Approved CSP System Alongside Comprehensive Training and Expert Support
News | Pacemakers
Biotronik Introduces World’s First and Only System CE Approved for Left Bundle Branch Area Pacing (LBBAP)

March 15, 2024 — Following the recent CE approval of the Solia S lead1 for LBBAP, Biotronik announces the world’s first ...

Home March 15, 2024
Home
Partnership targets heart failure, the leading cause of death and a condition with limited treatment options
News | Heart Failure
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership

March 15, 2024 — BioCardia, Inc., a biotechnology company focused on advancing late-stage cell therapy interventions for ...

Home March 15, 2024
Home
Partnership targets heart failure, the leading cause of death and a condition with limited treatment options
News | Cardiovascular Business
Gilbert H. L. Tang Appointed Editor-in-Chief of JACC: Case Reports

March 15, 2024 —Renowned cardiovascular surgeon Gilbert H. L. Tang, MD, has been named Editor-in-Chief of JACC: Case ...

Home March 15, 2024
Home
In a new letter sent to federal officials on March 12, the American Medical Association (AMA) has presented six relief proposals to support physicians impacted by Change Healthcare hack, and praised the creation of the Change Healthcare/Optum Payment Disruption (CHOPD) Accelerated Payments.
News | Cybersecurity
AMA Presents Relief Proposals to Federal Officials to Support Physicians Impacted by Change Healthcare Hack

March 14, 2024 — The American Medical Association (AMA) has issued a new letter to federal officials in which it praised ...

Home March 14, 2024
Home
First-of-its-kind trial in US shows drug-coated balloons are a superior treatment option for patients undergoing coronary angioplasty
News | Cardiovascular Clinical Studies
BIDMC-led Trial Leads to FDA approval of Coronary Drug-coated Balloons

March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led ...

Home March 13, 2024
Home
BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Centers for Medicare & Medicaid Services (CMS) approval for reimbursement coverage of the confirmatory Phase III clinical trial of CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure.
News | Heart Failure
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study

March 13, 2024 — BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2024
Home
New Jersey-based Atlantic Health System’s Morristown Medical Center and New York-based NYU Langone Health, both nationally recognized cardiovascular programs, have announced that they are expanding their partnership to provide patients improved access to adult congenital heart disease services and the specialist directed care. Shown here, Trish O’Keefe, Senior Vice President, and President of Morristown Medical Center.
News | Cardiovascular Business
Atlantic Health System’s Morristown Medical Center and NYU Langone Health Expand Partnership to Include Adult Congenital Heart Disease

March 13, 2024 — Two nationally recognized cardiovascular programs, New Jersey-based Atlantic Health System’s Morristown ...

Home March 13, 2024
Home
Silence Therapeutics has announces positive topline 36-week data from its ongoing Phase 2 Study of Zerlasiran in patients with high Lipoprotein(a), reporting that the study met the primary endpoint and demonstrated highly significant reductions in Lp(a) to week 36.
News | Cardiovascular Clinical Studies
Positive Topline 36-Week Data from Ongoing Phase 2 Study of Zerlasiran in Patients with High Lp(a) Announced by Silence Therapeutics

March 13, 2024 — Silence Therapeutics has announced positive topline 36-week data from the ongoing ALPACAR-360 phase 2 ...

Home March 13, 2024
Home
Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States
News | Structural Heart
New Late-breaking Data from Medtronic Evolut Low Risk Trial Demonstrate Strong Clinical and Cost-effectiveness Benefits of TAVR Platform

March 12, 2024 — Medtronic plc, a global leader in healthcare technology, today announced two late-breaking data ...

Home March 12, 2024
Home
Physicians at Vilnius University Hospital. Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, today announced that it has launched its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States
News | Robotic Systems
Stereotaxis Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States

March 12, 2024 — Stereotaxis, a pioneer and global leader in surgical robotics for minimally invasive endovascular ...

Home March 12, 2024
Home
Getinge has announced the U.S. Food and Drug Administration’s (FDA) 510(k) clearance of the Vasoview Hemopro 3, the latest addition to the medtech company’s endoscopic vessel harvesting (EVH) solutions.
News | FDA
Getinge Announces US FDA 510(k) Clearance for Vasoview Hemopro 3 Endoscopic Vessel Harvesting (EVH) solution

March 12, 2024 — Getinge has announced the U.S. Food and Drug Administration’s (FDA) 510(k) clearance of the Vasoview ...

Home March 12, 2024
Home
The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling its HeartMate Touch System (version 1.0.32) for risk of unexpected pump stop or start. Issues may occur if the HeartMate Touch System is disconnected from a patient’s HeartMate Controller while a “pump stop” command is running. People who have the implantable HeartMate 3 Left Ventricular Assist Device may be affected.
News | FDA
FDA Announces Abbott Recall of HeartMate Touch Communication System for Unintentional Pump Start and Stop

March 12, 2024 — The U.S. Food and Drug Administration (FDA) announced that Abbott is recalling its HeartMate Touch ...

Home March 12, 2024
Home
VahatiCor, Inc., a med tech company dedicated to helping patients with persistent ischemic heart disease, has announced the treatment of the first patient with the A-FLUX Reducer System, a treatment for patients with angina or chest pain.
News | Cardiovascular Business
VahatiCor, Inc. Announces Treatment of First Patient with the A-FLUX Reducer System Innovation for Patients Suffering from Angina Due to Persistent Ischemic Heart Disease

March 11, 2024 — VahatiCor, Inc., a med tech company dedicated to helping patients with persistent ischemic heart ...

Home March 11, 2024
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now